| Name | Enalapril |
| Description | Enalapril is a dicarbocyl-containing peptide and angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. |
| Kinase Assay | PDGF receptor kinase activity: PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : Soluble
DMSO : 55 mg/mL (146.1 mM), Sonication is recommended.
|
| Keywords | MRP1 | MK421 | MK 421 | Inhibitor | inhibit | Enalapril | Antihypertensives | Angiotensin-converting Enzyme (ACE) | ACE inhibitor | ACE |
| Inhibitors Related | Tranilast | Prednisone | Lisinopril dihydrate | Telmisartan | Sacubitril/Valsartan | Benzyl benzoate | Irbesartan | Losartan | Cyclophosphamide | Flurbiprofen | Captopril | Cholesterol |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | FDA-Approved Drug Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bitter Compound library | Bioactive Compounds Library Max | Anti-Hypertension Compound Library |
United States
